Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0376358 (
prostate cancer
)
59,338
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
DEP domain-containing protein 1B
(
DEPDC1B
) has been reported to serve important functions in breast cancer and non-small cell lung cancer. However, its involvement in the development of
prostate cancer
(PCa) remains unclear. Therefore, the present study aimed to investigate the expression and clinical significance of
DEPDC1B
in tumor tissues from patients diagnosed with PCa. A total of 80 prostate tissue samples were collected following prostatectomy to generate a tissue microarray for immunohistochemical analysis of
DEPDC1B protein
expression. High throughput sequencing of mRNAs from 179 prostate tissue samples, either from patients with PCa or from healthy controls, was included in the Taylor dataset. The expression levels of
DEPDC1B
in tumor tissues from patients with PCa were revealed to be significantly increased compared with those in normal prostate tissues (P=0.039). Increased expression of
DEPDC1B
was significantly associated with advanced clinical stage (P=0.006), advanced T stage (P=0.012) and lymph node metastasis (P=0.004). Kaplan-Meier analysis demonstrated that patients with high levels of
DEPDC1B
mRNA had significantly shorter biochemical recurrence (BCR)-free survival times. Multivariate analysis using Cox proportional hazards model revealed that levels of
DEPDC1B
mRNA were significant independent predictors of BCR-free survival time of patients with PCa. Therefore, the expression of
DEPDC1B
may be used as an independent predictor of biochemical recurrence-free survival time of patients with PCa.
...
PMID:High levels of DEPDC1B predict shorter biochemical recurrence-free survival of patients with prostate cancer. 2916 1
